Hubei Bio-pharmaceutical Industrial Technological Institute Inc.

Humanwell Healthcare (group) Co., Ltd.

Medshine Discovery Inc.

Wuhan Optics Valley Humanwell Bio-pharmaceutical Co., Ltd.

Hubei Biological Medicine Industrial Technology Institute Co., Ltd.

Wuhan Chemligand Bio-pharmaceutical Co., Ltd.

Humanwell Healthcare Co., Ltd.

Xuehai Wang

Yong Xu

Lu Huang

Ronghua Tu

Wenjie Sun

Hailiang Chen

Shuhui Chen

Yong Wang

Lie Li

Cailin Wang

Jie Shen

Zhongwen Yang

Yang Yue

Qiang Xiao

Charles Z Ding

Zheng Wang

Cong Wang

Hui Liu

Weidong Li

Yang YuE

Jing Yang

Yanping Yu

Hua Tian

Jimeng Wang

Biao Deng

Li'e Li

Guoping Hu

Chengde Wu

Yi Zhang

Zhaozhong Ding

Jian Li

Chunli Shen

Zhibo Zhang

Zhiyu Liu

Jie Li

Wen Zhou

Gang Chen

Jing Tang

Nengyang Shi

Quan Liu

Zhenyu He

Xuwen Zhang

Xijun Sheng

Xiaolin Zhang

Tianci Huang

Zhaoze Fan

Yun Feng

Rubin Cao

Hangui Xia

Diliang Guo

Jing Yu

Chengbing Yang

Gang Li

Zhongsheng Liu

Lei Zhao

Peng Wang

Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1, 5-alpha]benzimidazole compound and the preparation method and intermediate thereof. The 4H-pyrazolo[1,5-alpha]benzimidazole compound has the structure of Compound 2. 

Salt type and crystal type of 4h-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof

The present invention provides a pyrimidine derivative and a use thereof. The pyrimidine derivative is the compound shown in formula I or a pharmaceutically acceptable salt, hydrate, solvate, metabolite or prodrug thereof, wherein, R, R, R, Rand Rare, for example, as defined in the specification. The compound can act as an ALK inhibitor, and is for preparing an anti-tumor medicament for suppressing an anaplastic lymphoma kinase. 

Pyrimidine derivative and use thereof

Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV). 

BTK inhibitor

Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1,5-alpha]benzimidazole compound and a preparation method and intermediate thereof. The 4H-pyrazolo[1,5-alpha]benzimidazole compound is represented by formula I: 

Salt type and crystal type of 4H-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof

Disclosed is a series of analogs of 4H-pyrazolo[1,5-&#x3b1;]benzimidazole compound as PARP inhibitors. In particular, disclosed in the invention is a compound as shown by formula (I) or a pharmaceutically acceptable salt thereof as a PARP inhibitor.

Analogues of 4H-pyrazolo[1,5-a] benzimidazole compound as PARP inhibitors

A capsule containing total flavonoids of, a method for preparing the same and a use of the capsule containing total flavonoids ofare provided. Specifically, the capsule includes total flavonoids ofprovided in a form of alcohol extract ofand a pharmaceutically acceptable excipient.

Capsule containing total flavonoids of desmodium styracifolium, method for preparing the same and use

Growing community of inventors

Hubei, China

Xuehai Wang